ESTIMATION OF ORAL CYSTEAMINE BITARTRATE AT STEADY STATE IN CYSTINOSIS

胱氨酸中毒稳态时口服半胱胺酒石酸氢盐的估计

• 批准号: 6265204
• 负责人: JERRY A SCHNEIDER
• 金额: $ 1.15万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6265204
• 关键词: blood chemistry; clearance rate; clinical research; cysteamine; cystinosis; dosage; drug screening /evaluation; human subject; human therapy evaluation; leukocytes; longitudinal human study; metabolism disorder chemotherapy; oral administration

Blood draws to determine white blood cell cystine and plasma cysteamine levels at hours .5, 1, 1.5, 2,3 and 6 post dosing in patients who have reached their maximum dose of cystagon and who have maintained this dose for at least 6 months. Evaluate the clearance of cystagon over the patient's 6 hour dose interval.

每小时抽血测定白细胞半胱氨酸和血浆半胱胺水平。对于已达到cystagon最大剂量并维持该剂量至少6个月的患者，在给药后进行5、1、1.5、2、3和6次治疗。在患者6小时的给药间隔内评估cystagon的清除率。